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INTRODUCTION
Ischaemic heart disease (IHD) is the 
most common cause of death worldwide, 
accounting for 12.7% of total global mortality 
in 2008.1 Interventions that halt or slow the 
progress of IHD once it has been detected 
(secondary prevention), to prevent further 
events among those with established 
heart disease, are widely advocated and 
promoted.2 Two systematic reviews of 
secondary cardiac prevention programmes 
conducted in 2001 and 2005 demonstrated 
improved processes of care3 and improved 
patient outcomes.4 However, both noted 
evidence of a ‘ceiling effect’, whereby 
interventions have a diminishing beneficial 
effect once certain levels of risk factor 
management are reached. Both reviews 
recommended rigorous evaluation of long-
term clinical and economic outcomes. 
In 2010, a Cochrane Review5 assessed 
the effectiveness of service organisation 
interventions that aimed to improve the 
delivery of secondary preventative care in 
primary care or community settings. The 
review concluded that there was weak 
evidence regarding the effectiveness of 
such interventions in improving compliance 
with target levels of cholesterol and blood 
pressure. The Cochrane Review considered 
data collected at the end of interventions, 
varying from 12 to 36 months. The present 
study aimed to systematically review, and 
where possible, conduct a meta-analysis 
of, the evidence from follow-up studies 
of randomised controlled trials (RCTs), 
evaluating the long-term effectiveness of 
organisational interventions for people with 
IHD in primary care or community settings. 
These organisational interventions aim to 
alter the way existing secondary prevention 
services are arranged; for example, by the 
introduction of a structured recall system 
and specific secondary prevention clinics, 
in which modifiable lifestyle risk factors 
and prescribed medications are reviewed. 
Primary care or a community setting is 
where most of the ongoing, long-term 
managing of IHD takes place and is defined 
as the first point of access to healthcare 
services, where clinicians are responsible 
for most personal healthcare needs and 
aim to develop and maintain a long-term 
relationship with patients and families.6
METHOD
The protocol for this systematic review is 
available on the PROSPERO register7 and 
the review was undertaken using Cochrane 
methodology.8
Inclusion criteria
Studies were included in which the original 
intervention lasted a minimum of 12 months 
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Abstract
Background
Ischaemic heart disease (IHD) is the most 
common cause of death worldwide.
Aim
To determine the long-term impact of 
organisational interventions for secondary 
prevention of IHD.
Design and setting
Systematic review and meta-analysis of studies 
from CENTRAL, MEDLINE®, Embase, and 
CINAHL published January 2007 to January 
2013.
Method
Searches were conducted for randomised 
controlled trials of patients with established 
IHD, with long-term follow-up, of cardiac 
secondary prevention programmes targeting 
organisational change in primary care or 
community settings. A random-effects model 
was used and risk ratios were calculated. 
Results
Five studies were included with 4005 
participants. Meta-analysis of four studies 
with mortality data at 4.7–6 years showed that 
organisational interventions were associated 
with approximately 20% reduced mortality, with 
a risk ratio (RR) for all-cause mortality of 0.79 
(95% confidence interval [CI] = 0.66 to 0.93), 
and a RR for cardiac-related mortality of 0.74 
(95% CI = 0.58 to 0.94). Two studies reported 
mortality data at 10 years. Analysis of these 
data showed no significant differences between 
groups. There were insufficient data to conduct 
a meta-analysis on the effect of interventions on 
hospital admissions. Additional analyses showed 
no significant association between organisational 
interventions and risk factor management or 
appropriate prescribing at 4.7–6 years.
Conclusion
Cardiac secondary prevention programmes 
targeting organisational change are associated 
with a reduced risk of death for at least 
4–6 years. There is insufficient evidence to 
conclude whether this beneficial effect is 
maintained indefinitely.
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and was evaluated in a RCT, randomised 
by individual or by cluster. Follow-up must 
have occurred a minimum of 12 months 
after the end of the intervention.
Interventions targeted at organisational 
change in primary or community 
care settings were included, where the 
intervention was aimed at improved 
clinician and patient adherence with 
recommendations on secondary 
prevention of IHD. It was noted that on 
study completion, interventions could have 
formally ended or could have continued 
and been delivered to control patients. The 
plan was to explore intervention activity and 
contamination of control patients during 
the observational follow-up period. The 
comparator was ‘usual care’, although it 
is likely that baseline levels of secondary 
prevention care varied significantly between 
different settings. Interventions that were 
delivered exclusively by research personnel 
or hospital-based staff, without a planned 
link to primary or community care clinicians 
were excluded.
Studies were included of patients with 
established IHD: documented myocardial 
infarction, coronary artery bypass grafting, 
percutaneous transluminal coronary 
angioplasty, coronary artery stent, or 
angina. 
Search strategy and data extraction
The search was conducted on Cochrane 
Central Register of Controlled Trials 
(CENTRAL), MEDLINE®, Embase, and 
CINAHL in January 2013 (Appendix 1). The 
search was based on that used in the 
Cochrane Review in 2010,5 and limited to 
articles published from 2007 onwards, 
with no language restrictions. One author 
screened the titles for eligibility. Two authors 
independently screened the abstracts 
of the retained citations in duplicate and 
assessed full-text reports of all potentially 
relevant studies for eligibility. Two authors 
completed data extraction in duplicate, 
extracting details on patients, interventions, 
comparators, outcome measures, study 
design, follow-up data collection, risk of 
bias and informal intervention activity, and 
potential contamination during the follow-
up period. Where insufficient data were 
reported, study authors were contacted 
for further information. Disagreements 
were resolved by consultation with another 
author when required.
Statistical analysis
The primary outcomes were mortality 
and hospital admissions (all-cause and 
cardiac). These outcomes were considered 
to be of greatest relevance to assessing 
long-term outcomes of interventions as 
they are direct measures of impact on 
people’s wellbeing and health. Secondary 
outcomes were risk factor management 
(blood pressure, cholesterol, and 
smoking status), appropriate prescribing 
of secondary prevention medications 
according to national guidelines, for 
example, prescribing of statins to reduce 
lipids to target levels, and health status, as 
measured by validated scales, for example, 
SF-12. Review Manager (RevMan, version 
5.2) was used for all analyses.
Where possible and appropriate, data 
from included studies were combined for 
each outcome. A random-effects model was 
used to produce an overall summary of the 
combined treatment effect across studies. 
For dichotomous data, summary risk ratios 
(RR) were calculated with 95% confidence 
intervals [CIs], and for continuous data, 
mean differences with 95% CIs. If data 
from trials randomised by cluster were 
not already adjusted to take the cluster 
effect into account, the sample sizes were 
adjusted using the methods described in 
the Cochrane Handbook,8 using an estimate 
of the intracluster correlation coefficient 
(ICC) derived from the trial where available 
or from trials of similar populations.9
Risk of bias assessment of included 
studies was conducted separately for the 
original RCTs and then for the observational 
follow-up studies, using the appropriate risk 
of bias assessment methods recommended 
in the Cochrane Handbook.8 Statistical 
heterogeneity was assessed in each meta-
analysis and heterogeneity regarded as 
substantial where t²>0 and either I²>50% 
or P<0.1 in the χ² test for heterogeneity.
RESULTS
From the 10 294 citations identified in 
the search, and two additional citations 
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How this fits in
This systematic review shows that cardiac 
secondary prevention programmes 
for ischaemic heart disease targeting 
organisational change are associated with 
reduced mortality for at least 4–6 years, 
after the formal cessation of the original 
programmes. There is insufficient evidence 
to conclude whether this beneficial effect is 
maintained indefinitely. Further research is 
recommended on the long-term impact of 
organisational interventions in primary care 
on hospital admissions.
identified from the bibliography of the 
Cochrane Review,5 the full text of 71 articles 
(56 studies) was reviewed (Figure 1). Sixty 
articles (51 studies) were excluded, most 
commonly because the intervention was 
not based in primary care.
Included studies
Five randomised controlled trials were 
identified for inclusion, involving 4005 
participants. Two trials were randomised 
by individual10,11 and three randomised by 
cluster, with randomisation by practice.12–14 
All five trials were conducted in Western 
Europe: in Northern Ireland,10 Scotland,11 
Spain,14 and Sweden,12 and the fifth in 
both the Republic of Ireland and Northern 
Ireland.13 Table 1 summarises the 
participant characteristics. Characteristics 
on the studies are available from the 
authors on request.
Several sources of potential heterogeneity 
were evident, including differences between 
study populations, target levels for risk 
factors, outcomes measured, and in usual 
care. In addition, there was variation in 
the intervention components, the length 
of the original interventions (varied from 
1–3 years), and the length of observational 
follow-up (four studies had follow-up data 
at 4.7–6 years,15–18 two studies had 10-year 
follow-up data19,20). Follow-up data were 
reported at two different times for the 
Scottish study: 4.7 years16 and 10 years.19 
Five different intervention components 
were combined in different ways across the 
included studies (Table 1): patient education 
and pre-planned appointments (four 
studies) and clinician education, nurse-led 
interventions, and risk-factor management 
(three studies). The sample sizes were 
adjusted where required in all three cluster-
randomised trials, using the methods 
recommended in the Cochrane Handbook.8
Care after the end of the formal 
intervention
The formal intervention ceased at the 
end of the original studies. In the three 
trials randomised by cluster, the risk of 
contamination of control patients during 
follow-up was slight, with no formal roll-
out to control practices and cessation of 
support to intervention practices.17,18,20 In 
the trials randomised by individual,15,16 
control, and intervention patients attended 
the same practices so some contamination 
may theoretically have occurred on study 
completion. This was formally assessed in 
the Scottish study,16 where many practices 
continued to offer the secondary prevention 
clinics to all patients. Fifty-five per cent of 
control patients had attended at least one 
secondary prevention clinic after 4 years.
Risk of bias
Overall, the original intervention and the 
follow-up component of the five included 
studies were of reasonable quality 
(Figure 2). All studies conducted satisfactory 
random sequence generation and adequate 
allocation concealment. Apart from one 
study,12 participants and personnel were not 
blinded to allocation because of the nature 
of the intervention. Three studies15,18,20 had 
adequate blinding of outcome assessors 
at follow-up. The review authors concluded 
that lack of blinding of outcome assessors 
at follow-up did not affect mortality data but 
other outcome data collected from practice 
records were at high or unclear risk of bias.
As outlined above, two of the five studies 
may have had some contamination of 
control patients in the follow-up period.15,16 
Loss to long-term follow-up was very low 
for mortality data (<2%) but was >20% 
in all studies for other outcomes. Only 
one of the five included studies15 reported 
all the outcomes at follow-up that had 
been reported at the end of the original 
intervention study.
Figure 1. Selection process for eligible randomised 
controlled trials with long-term follow-up from all 
identified citations.
9703 records excluded 
60 full-text articles 
excluded (51 studies) 
35 studies not primary care 
5 studies participants do not 
meet inclusion criteria 
3 studies no long-term follow-up
2 studies intervention 
<12 months 
6 studies other reasons 
5 studies included in 
qualitative synthesis 
(11 citations) 
5 studies included in 
quantitative synthesis 
(meta-analysis) 
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10 294 records identified 
through database searching 
2 additional records identified 
through other sources 
9774 records after duplicates removed 
9774 records screened 
71 full-text articles 
assessed for eligibility 
(56 studies)
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Effects of intervention 
Mortality. Four studies15–18 reported data on 
2803 participants for all-cause mortality 
at follow-up between 4.7 and 6 years. 
Murchie et al16 reported a significantly 
reduced risk ratio for the Scottish study, 
but the other three studies showed a non-
significant reduced risk ratio favouring the 
intervention. Meta-analysis of all-cause 
mortality data produced a risk ratio of 
0.79 (95% CI = 0.66 to 0.93) in favour of 
the intervention (Figure 3). This suggests 
that organisational interventions were 
associated with a reduction of overall risk of 
death of approximately 20%, a finding that is 
strengthened by the fact that no measurable 
statistical heterogeneity between studies 
was detected (t² = 0.00; P = 0.90, I² = 0%).
Data on cause of death were reported or 
available from authors for the four studies. 
Cause of death was classified as cardiac, 
defined as death from any coronary or 
cardiovascular cause, or non-cardiac. One 
study15 showed a significantly reduced risk 
ratio favouring the intervention, but the other 
three studies showed a non-significant 
reduced risk ratio favouring the intervention. 
Meta-analysis of data on 2765 participants 
for cardiac-related mortality produced a risk 
ratio of 0.74 (95% CI = 0.58 to 0.94) in favour of 
the intervention (Figure 4). This suggests that 
organisational interventions were associated 
with a 26% reduction in risk of cardiac-related 
Table 1. Summary of included studies and participant characteristics
   Numbers  Length of    
  randomised, intervention (length What happened Components of Outcomes at follow-up 
Study Participants age, sex of follow-up) during follow-up? intervention considered in this review
Cupples 199410a Diagnosed angina 688, 63 years,  2 years (5 years) Intervention ceased • Patient education • Mortality 
and 199915b Age <75 years 59% male   • Pre-planned • Smoking habit 
Northern Ireland        appointments • Blood pressure 
     • Nurse-led • Serum total cholesterol 
      • Self-reported health  
         status (Nottingham  
         Health Profile)
Campbell 199811 Diagnosis of CHD 1343, 66 years,  1 year (4.7 years)  Intervention delivered • Patient education • Mortality 
Murchie 200316 or prescribed nitrates 58% male (10 years) to some patients in • Risk factor • Hospital admissions 
Delaney 200819 Age <80 years   control and intervention    management • Blood pressure 
Scotland     • Pre-planned • Serum total cholesterol 
        appointments • Self-reported health 
     • Nurse-led    status (SF36)
Kiesslingc 200212 Diagnosed angina 88, 62 years,  2 years (10 years) Intervention ceased • Clinician education • Mortality 
201120 Sweden or diagnosed MI 85% male    • Cause of death
Munozc 200714 Diagnosed angina 983, 64 years,  3 years (5 years) Intervention ceased • Patient education • Mortality 
200817 or MI within 6 years 72% male   • Clinician education 
Spain Age 30–79 years    • Risk factor 
        management 
     • Pre-planned 
        appointments
Murphyc 200913 Previous MI, CABG, 903, 67 years,  18 months (6 years) Intervention ceased • Patient education • Mortality 
201418 PTCA, diagnosed 75% male   • Clinician education • Hospital admissions 
Republic of Ireland angina    • Risk factor • Blood pressure 
and Northern Ireland        management • Serum total cholesterol 
     • Pre-planned • Self-reported health 
        appointments    status (SF12) 
     • Nurse-led
a First date refers to the date of publication of main study results. b Second (and subsequent) dates refer to date of publication of long-term follow-up results. c Randomisation by 
cluster. CABG = coronary artery bypass grafting. CHD = coronary heart disease. MI = myocardial infarction. PTCA = percutaneous transluminal coronary angioplasty. 
Figure 2. Risk of bias of included studies. Detection 
bias, attrition bias, or reporting bias at the end of the 
original trial are not included. 
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of follow-up outcome assessment: mortality
Selective outcome reporting at follow-up
Incomplete outcome data at follow-up
Contamination of controls during follow-up
Other bias
Low risk of bias Unclear risk of bias High risk of bias
0% 25% 50% 75% 100%
Blinding of follow-up outcome assessment:
all other outcomes
Blinding of participants and personnel (performance bias)
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death, a finding that is strengthened by the 
measurable statistical heterogeneity detected 
between the studies (t² = 0.01; P = 0.33, I² = 
12%).
Meta-analysis of data from two studies19,20 
including 1346 participants at 10-year 
follow-up indicated no statistically significant 
difference between the two groups for 
all- cause mortality (RR 0.91, 95% CI = 0.75 
to 1.09) (Figure 5), with almost negligible 
statistical heterogeneity (t² = 0.01; P = 0.31, 
I² = 3%), or for cardiac-related mortality 
(RR 0.95, 95% CI = 0.79 to 1.16).
Hospital admissions. Two studies provided 
data on admissions at long-term follow-up. 
Murphy et al13 originally reported a significant 
reduction in mean hospital admissions 
at the end of an 18-month organisational 
intervention, but this difference between 
groups was not sustained at 6-year follow-
up.18 Delaney reported no significant 
difference in the total number of hospital 
admissions between groups after 10 years.19 
It was not possible to pool data on hospital 
admissions.
Risk factor management and prescribing 
for secondary prevention. Meta-analysis 
of data from three studies15,16,18 showed 
that organisational interventions were not 
associated with a significant change in 
numbers with blood pressure (RR 0.95, 95% 
CI = 0.83 to 1.09) or cholesterol (RR 0.98, 
95% CI = 0.89 to 1.07) within target levels 
(Table 2). Additional meta-analyses showed 
no significant changes in mean systolic 
blood pressure or mean total cholesterol 
associated with the interventions (Table 2). 
Only one study15 reported on smoking 
status at follow-up, self-reported current 
smoker (Yes/No) confirmed using a validated 
measurement, with no significant difference 
between the two groups.
Study or subgroup
Cupples 199915
Murchie 200316
Munoz 200817
Murphy 201418
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.01; χ2 = 3.42, df = 3 (P = 0.33); I2 = 12%
Test for overall effect: Z = 2.43 (P = 0.02)
32
74
7
15
128
Experimental
Events Total
341
639
167
235
1382
60
90
7
17
174
346
642
152
243
1383
Events Total Weight,%
30.6
51.5
5.5
12.4
100.0
Control
0.54 (0.36 to 0.81)
0.83 (0.62 to 1.10)
0.91 (0.33 to 2.54)
0.91 (0.47 to 1.78)
0.74 (0.58 to 0.94)
M-H, random (95% CI) 
Risk ratio Risk ratio
M-H, Random, 95% CI
0.01 0.1
Favours (experimental) Favours (control)
1 10 100
Figure 4. Organisational intervention versus usual care: death from cardiac causes, 4.7–6 years.
Figure 5. Organisational intervention versus usual 
care: all-cause mortality, 10 years.
Study or subgroup
Delaney 200811
Kiessling 201120
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.01; χ2 = 1.03, df = 1 (P = 0.31); I2 = 3%
Test for overall effect: Z = 1.03 (P = 0.30)
254
3
257
Experimental
Events Total
658
14
672
277
6
283
660
14
674
Events Total Weight,%
97.4
2.6
100.0
Control
0.92 (0.81 to 1.05)
0.50 (0.15 to 1.61)
0.91 (0.75 to 1.09)
M-H, random (95% CI) 
Risk ratio Risk ratio
M-H, random, 95% CI
0.01 0.1
Favours (experimental) Favours (control)
1 10 100
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Study or subgroup
Cupples 199915
Munoz 200817
Murchie 200316
Murphy 201418
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.57, df = 3 (P = 0.90); I2 = 0%
Test for overall effect: Z = 2.74 (P = 0.006)
47
18
100
34
199
Experimental
Events Total
342
167
658
235
1402
65
21
128
39
253
346
152
660
243
1401
Events Total Weight,%
24.5
8.3
51.1
16.2
100.0
Control
0.73 (0.52 to 1.03)
0.78 (0.43 to 1.41)
0.78 (0.62 to 0.99)
0.90 (0.59 to 1.38)
0.79 (0.66 to 0.93)
M-H, random (95% CI) 
Risk ratio Risk ratio
M-H, random, 95% CI
0.01 0.1
Favours (experimental) Favours (control)
1 10 100
Figure 3. Organisational intervention versus usual care: all-cause mortality, 4.7–6 years.
Meta-analysis of data from three 
studies15,16,18 and two studies15,18 showed no 
significant change at follow-up in prescribing 
of aspirin (RR 1.06, 95% CI = 1.00 to 1.12) 
or statins (RR 1.09, 95% CI = 0.77 to 1.53), 
respectively, associated with the interventions. 
As illustrated in Table 2, there was substantial 
clinical and statistical heterogeneity in some of 
the analyses around risk factor management 
and prescribing, so these results need to be 
interpreted with caution.
Patient-reported health status was 
measured in three studies, with none 
showing a significant difference between 
groups at follow-up.15,18,21 Meta-analysis was 
not possible because of differences between 
measurement scales.
DISCUSSION
Summary
This review considered whether cardiac 
secondary prevention programmes that 
targeted organisational change in primary 
care or community settings were associated 
with sustained improvements in patient 
outcomes. There were statistically significant 
differences in all-cause and cardiac-related 
mortality between intervention and control 
patients at follow-up over a 4.7–6 year time 
period, with approximately 20% reduction 
in all-cause mortality and 26% reduction in 
risk of cardiac-related death in intervention 
patients.
Only two studies provided follow-up data 
at 10 years and no significant reduction in 
mortality was observed. However, given this 
small number of studies it is not possible 
to say whether this relates to dissipation of 
the intervention effect on mortality over time 
or that this analysis was underpowered to 
detect a difference.
There were no significant differences in 
risk factor management or prescribing for 
secondary prevention over the 4.7–6 year 
follow-up period, and the one study that 
had originally reported significant reductions 
in hospital admissions found no significant 
differences at follow-up. After a minimum 
follow-up period of 4.7 years in the studies 
included in this review, substantial numbers 
of intervention patients with known IHD 
have blood pressure and total cholesterol 
above target levels (blood pressure 38% 
above target; total cholesterol 55% above 
target). However, differences between 
included studies in the study populations, 
the intervention components, and risk factor 
target levels over time make interpretation 
of the risk factor and prescribing data 
difficult; this also suggests that other factors 
contribute to the apparent improved survival 
but there is insufficient evidence available 
to reach any conclusion regarding other 
factors, such as diet or exercise.
Strengths and limitations
This systematic review was conducted using 
Cochrane methodology and reported using 
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Table 2. Summary of meta-analysis results: categorical and continuous outcomes
  Included studies, Intervention Control Risk ratio M-H, 
 Outcome n Events Total Events Total random (95% CI) Heterogeneity, I2
At 4.7–6 years: categorical outcomes 
Mortality  Mortality (all-cause) 4 199 1402 253 1401 0.79 (0.66 to 0.93) 0%
 Cardiac cause of death 4 128 1384 174 1385 0.74 (0.58 to 0.94) 12%
Risk factor BP within guidelines 3 624 1016 623 1005 0.95 (0.83 to 1.09) 61%
management Total cholesterol 3 417 950 397 879 0.98 (0.89 to 1.07) 0% 
 within guidelines
Secondary prevention Aspirin prescribed 3 687 958 631 939 1.06 (1.00 to 1.12) 39%
prescribing Statins prescribed 2 212 472 213 493 1.09 (0.77 to 1.53) 75%
At 10 years: categorical outcomes 
Mortality Mortality (all-cause) 2 257 672 283 674 0.91 (0.75 to 1.09) 3%
 Cardiac cause of death 2 152 672 160 674 0.95 (0.79 to 1.16) 0%
At 4.7–6 years: continuous outcomes 
  Included studies,    Mean differenceb   
 Outcome  n Intervention, n Control, n (95% CI) Heterogeneity, I2
Risk factor Mean difference systolic 2 469 466 1.94 (–3.02 to 6.91) 70% 
management BP (mmHg)
 Mean difference total 2 362 358 0.03 (–0.12 to 0.18) 0% 
 cholesterol (mmol/l)
BP = blood pressure. aMantel-Haenszel, random effects. bInverse variance, random effects. 
the PRISMA guidelines.8,22 The protocol 
was published on the PROSPERO register. 
Potential limitations relate to generalisability 
of findings, as the populations included in 
the trials were predominantly males with a 
mean age range of 62–67 years and located 
in Western Europe, and to the clinical 
heterogeneity of interventions. In addition, 
the small number of included studies did 
not allow for sensitivity analysis based on 
risk of contamination of controls.
In general, there is insufficient evidence to 
determine how long a service organisation 
intervention can continue to have an impact 
after the intervention has ended, the impact 
of contamination because of cross-over 
during the follow-up periods, and the 
changes in usual care practices over the 
follow-up period.
Implications for policy and research 
This review raises important questions 
about components and sustainability of 
effects of organisational interventions for 
secondary prevention of IHD. There was 
considerable heterogeneity in interventions 
in the included studies and many studies 
did not describe exact details of intervention 
components as has been recommended 
recently.23 Most studies included pre-
planned appointments and patient 
education, although the intensity of both 
varied between studies. Therefore, there 
is limited information about how these 
interventions brought about changes in 
patient outcomes and the process of care. 
Although the interventions did vary, this 
reflects what would happen in practices 
if a health system introduced secondary 
cardiovascular prevention programmes 
with an organisational focus. This is 
consistent with the pragmatic nature of the 
studies included in this review.
This review suggests that organisational 
interventions are associated with clinically 
important outcomes in relation to mortality. 
The data included suggest that further 
improvements in risk factor management 
for those with levels above guideline targets 
is possible and could improve outcomes 
further. They indicate that mortality 
benefits occur for at least 4–6 years after 
formal cessation of interventions, despite 
potential contamination of control patients, 
suggesting that resources supporting 
targeted interventions over shorter time 
periods can lead to sustained benefits 
that persist beyond the duration of the 
interventions.
Further research to measure the long-
term impact of service organisation 
interventions on hospital admissions for IHD 
is recommended, especially in the current 
climate of increased costs of inpatient care 
and constrained budgets.
Therefore, there is limited information 
about causal pathways between 
interventions aimed at behavioural 
change and outcomes. Future research 
should test specific theories about how 
interventions work24 in terms of effecting 
patient and practitioner behaviour change. 
It is also necessary to identify for how 
long these behavioural changes persist 
without ongoing or intermittent exposure to 
interventions.
Cardiac secondary prevention 
programmes appear to have an impact on 
mortality in the longer-term, even after the 
formal cessation of such programmes and 
in spite of potential contamination of original 
control groups because of cross-over. This 
provides reassurance to practitioners that 
current efforts in secondary prevention 
are worthwhile. Consideration should be 
given to targeting secondary prevention 
programmes at populations with 
persistently high levels of risk and where 
the current level of care is suboptimal.
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Appendix 1. Search strategy
The authors searched CENTRAL (The Cochrane Library, Issue 12, December 2012), MEDLINE® on OVID 
(including MEDLINE® Daily Update 22 January 2013 and Ovid MEDLINE® In-Process & Other Non-Indexed 
Citations 22 January 2013), EMBASE on Ovid (January 2007 to January 2013) and CINAHL on EBSCO (January 
2007 to January 2013). The search was based on that used in the Cochrane Review in 2010, ENREF 5 modified 
to reflect the focus in this review on long-term outcomes. The search was limited to articles published from 
2007 onwards to cover the period following that review. No language or other limitations were imposed. 
Appendix 2 contains the MEDLINE search strategy. Contact was made with authors of studies included in the 
Cochrane Review ENREF 5 and authors of studies published since 2007 that met the inclusion criteria apart 
from the requirement for follow-up, to establish whether any long-term follow-up data had been collected but 
had not yet been published.
  1 exp Myocardial Ischemia/ 335 677
 2 Heart Diseases/ 52 711
 3 angina.tw. 42 059
 4 (heart adj3 disease$).tw. 120 550
 5 (coronary adj3 disease$).tw. 101 291
 6 myocardial infarct$.tw. 133 877
 7 exp Myocardial revascularization/ 75 836
 8 (coronary adj3 bypass$).tw. 35 114
 9 cabg.tw. 11 519
10 (coronary adj3 angioplast$).tw. 13 338
11 ptca.tw. 6062
12 (heart adj3 infarct$).tw. 5476
13 postmyocardial infarct$.tw. 795
14 or/1-13 517 186
15 delivery of health care/ 59 683
16 patient care management/ 2080
17 comprehensive health care/ 5925
18 nursing process/ 6198
19 exp nursing assessment/ 29 817
20 exp patient care planning/ 49 053
21 Patient-Centered Care/ 8972
22 "delivery of health care, integrated"/ 7454
23 exp managed care programs/ 38 300
24 disease management/ 9340
25 exp patient care team/ 51 103
26 exp Primary Health Care/ 71 178
27 Physicians, Family/ 14 346
28 Family Practice/ 58 725
29 Physicians, General Pract$/ 1165
30 General Practice/ 2144
31 Reminder Systems/ 1943
32 interdisciplinary communication/ 8495
33 Guideline Adherence/ 17 546
34 "Continuity of Patient Care"/ 13 241
35 home care services/ 26 352
36 home nursing/ 7784
37 ambulatory care/ 33 910
38 patient discharge/ 17 015
39 (manag$ adj3 care).tw. 31 702
40 (management adj3 program$).tw. 10 433
41 (case adj3 manag$).tw. 12 226
42 (patient adj3 management).tw. 20 622
43 (home adj3 intervention$).tw. 1346
44 (home adj3 care).tw. 19 309
45 (home adj visit).tw. 1247
 
46 (ambulatory adj care).tw. 6246
47 (discharg$ adj3 program$).tw. 617
48 (practice adj guideline).tw. 2428
49 (discharg$ adj3 planning).tw. 2134
50 (comprehensive adj3 care).tw. 5669
51 (treatment adj3 plan$).tw. 38 159
52 (nurse$ adj3 led).tw. 1862
53 (disease adj management).tw. 6939
54 multi-disciplin$.tw. 2916
55 multidisciplin$.tw. 38 309
56 exp Communication/ 333 646
57 (service$ adj3 organi$).tw. 5122
58 Nurse's Role/ 30 889
59 Nurse Practitioners/ 14 627
60 Community Health Services/ 25 576
61 Medical Audit/ 13 932
62 Nursing Audit/ 2908
63 audit.tw. 20 307
64 secondary prevention clinic$.tw. 41
65 general practi$.tw. 57 322
66 primary care.tw. 62 204
67 reminder$.tw. 6120
68 family practic$.tw. 7133
69 recall$.tw. 41 338
70 (Nurse adj3 clinic$).tw. 4408
71 (secondary prevention adj3 intervention$).tw. 231
72 (secondary prevention adj3 program$).tw. 396
73 "Appointments and Schedules"/ 6492
74 appointment$.tw. 11 880
75 (follow$up or long$term or aftercare).ti,ab. 22 777
76 or/15-75 1 048 082
77 randomized controlled trials/ 82 540
78 random allocation/ 75 988
79 double-blind method/ 117 201
80 single-blind method/ 16 890
81 (clin$ adj25 trial$).ti,ab. 230 106
82 ((singl$ or doubl$ or trebl$ or tripl$) adj 119 106 
 (blind$ or mask$)).ti,ab. 
83 research design/ 72114
84 random$.ti,ab. 623 725
85 or/77-84 954 576
86 14 and 76 and 85 2868
87 exp animal/ not humans/ 3 750 242
88 86 not 87 2866
89 limit 88 to yr="2007 - 2013" 1086
90 remove duplicates from 89 1078  
